Stoke Therapeutics (NASDAQ:STOK) Trading Down 5.4% - Time to Sell?

Key Points

• Stoke Therapeutics shares fell 5.4% to $20.80, with trading volume dropping 90% below the average, signaling potential concerns among investors.
• Analysts maintain an overall positive outlook with a consensus target price of $25.57, as multiple firms, including Cantor Fitzgerald and Jefferies Financial Group, issued "buy" ratings.
• Despite the stock decline, the company reported better-than-expected earnings per share of ($0.40), exceeding consensus estimates of ($0.57).

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) shares fell 5.4% on Tuesday . The company traded as low as $21.03 and last traded at $20.80. 82,366 shares were traded during mid-day trading, a decline of 90% from the average session volume of 807,927 shares. The stock had previously closed at $21.99.

Analysts Set New Price Targets

A number of analysts have recently issued reports on STOK shares. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Jefferies Financial Group started coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 price objective on the stock. Wedbush lifted their price objective on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Chardan Capital reiterated a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat, Stoke Therapeutics has an average rating of "Buy" and a consensus target price of $25.57.

Stoke Therapeutics Stock Down 2.1%

The company has a 50-day simple moving average of $15.13 and a two-hundred day simple moving average of $11.15. The stock has a market cap of $1.18 billion, a P/E ratio of 25.34 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%.The firm had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the sale, the insider owned 18,469 shares of the company's stock, valued at approximately $366,979.03. This trade represents a 22.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 14,922 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $20.14, for a total value of $300,529.08. Following the sale, the general counsel directly owned 18,176 shares in the company, valued at $366,064.64. This trade represents a 45.08% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 107,719 shares of company stock valued at $2,063,359 over the last quarter. 9.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after acquiring an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after acquiring an additional 5,084 shares in the last quarter. Osaic Holdings Inc. raised its position in shares of Stoke Therapeutics by 263.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company's stock worth $85,000 after acquiring an additional 5,427 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in shares of Stoke Therapeutics by 33.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company's stock worth $108,000 after acquiring an additional 2,384 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.